Home > Insider Trading > Filing (0001213900-18-002971)

Filing Details

Accession Number:: 0001213900-18-002971
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-03-14 16:30:07
Reporting Period:: 2014-02-03

Accepted Time:: 2018-03-14 16:30:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
707511	Regenerx Biopharmaceuticals Inc	RGRX	Pharmaceutical Preparations (2834)	521253406

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1495790	S.a. Sinaf	26, Boulevard Royal Luxembourg N4 L-2449		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-02-03	64,575	$0.00	11,584,795	No	4	J	Direct
Common Stock	Disposition	2018-03-13	11,584,795	$0.23	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	J	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Convertible Promissory Note (right to buy)	Disposition	2018-03-13	0	$150,000.00	0	$0.06

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2013-09-12		No	4	S	Direct

Footnotes

Represents shares escheated to the State of Delaware by the transfer agent. The reporting person did not receive notice of the escheatment and became aware that such shares were escheated during an internal review in 2017. The reporting person has submitted a claim for the payment of the market value of such shares.
Represents shares sold by the reporting person and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and the reporting person (the "Purchase Agreement").
Represents a $150,000 convertible promissory note (the "Note") sold by the reporting person and purchased by Essetifin for an aggregate of $183,780.82, pursuant to the Purchase Agreement. The reporting person purchased the Note on September 12, 2013, from the issuer in a private placement. The Note and any accrued interest thereon are convertible at the option of the holder at any time prior to repayment of the Note into common stock at a conversion price of $0.06 per share. The Note is payable upon the written demand of the holder thereof at any time after September 10, 2018 (the "Maturity Date"). Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the Maturity Date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date.